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Abstract
Renal tubules represent an intercellular unit and function as 
a syncytium. When acute tubular necrosis was first visualized 
to occur through a process of synchronized regulated necro-
sis (SRN) in handpicked primary renal tubules, it became ob-
vious that SRN actually promotes nephron loss. This realiza-
tion adds to our current understanding of acute kidney in-
jury (AKI)-chronic kidney disease (CKD) transition and argues 
for the prevention of AKI episodes to prevent CKD progres-
sion. Because SRN is triggered by necroptosis and executed 
by ferroptosis, 2 recently identified signaling pathways of 
regulated necrosis, a combination therapy employing necro-
statins and ferrostatins may be beneficial for protection 
against nephron loss. Clinical trials in AKI and during the pro-
cess of kidney transplantation are now required to prevent 
SRN. Additionally, necrotic cell death drives autoimmunity 
and necroinflammation and therefore represents a thera-
peutic target even for the prevention of antibody-mediated 
rejection of allografts years after the transplantation process.
© 2018 S. Karger AG, Basel
The Caspase-Controlled Cell Death System
Apoptosis
It is beyond the scope of this review to refer to the data 
published on apoptosis in acute kidney injury (AKI). The 
interested reader is referred to a recent review in which 
Contribution from the AKI and CRRT 2018 Symposium at the 23rd In-
ternational Conference on Advances in Critical Care Nephrology, Man-
chester Grand Hyatt, San Diego, CA, USA, February 26–March 1, 2018. 
This symposium was supported in part by the NIDDK funded Univer-
sity of Alabama at Birmingham-University of California San Diego 
O’Brien Center for Acute Kidney Injury Research (P30DK079337).
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we discussed this topic in detail [1]. Along these lines, the 
caspase-controlled cell death system also includes pyrop-
tosis, a pathway that results in necrotic cell death down-
stream of inflammasomes activation. This format does 
not allow us to review this pathway in detail, as it has not 
been investigated in AKI yet. However, recent data sug-
gest that it might be very important in AKI-chronic kid-
ney disease (CKD) progression [2].
Necroptosis
Necroptosis is an evolutionary conserved pathway of 
regulated necrosis (RN) to defend viruses that express 
caspase inhibitors. Caspase-8 controls the protein recep-
tor-interacting protein kinase 3 (RIPK3), the only known 
serin-theronine kinase that can phosphorylate the 
necroptosis executing pseudokinase MLKL (mixed lin-
eage kinase domain-like). pMLKL, by unknown means 
that involve the ESCRT-III complex [3], results in plas-
ma membrane rupture. With respect to AKI, RIPK3-de-
ficient mice [4] and MLKL-deficient mice [5] are pro-
tected from renal ischemia-reperfusion injury. Inhibi-
tion of necroptosis, therefore, appears to be a promising 
therapeutic target, but highly specific kinase inhibitors of 
RIPK1 (Nec-1s, ponatinib) did not protect from IRI in 
our hands (A.L., unpublished data). Obviously, there is a 
combination of several pathways of RN and its relative 
contribution to the overall organ damage of AKI is un-
clear today. 
It has recently been confirmed that the active produc-
tion of cytokines occurs during necroptosis progression 
[6], but precise mechanisms are incompletely under-
stood. However, the prevention of necroptosis signaling 
by necrostatins should prevent the release of immune 
modifying cytokines, but it remains unclear if necro-
statins affect CD8+ T-cell cross priming [7]. If RN-path-
ways specifically shape the immune response, a novel hy-
pothesis emerges and we refer to it as necroinflammation 
[8]. Box 1 summarizes the most important open ques-
tions with respect to necroinflammation during AKI.
The Lipid Peroxidation/Autoxation-Controlled 
Necrosis System
Ferroptosis
Ferroptosis is an iron-dependent cell death pathway 
that involves specific lipid peroxidation patterns that are 
involved in plasma membrane rupture [9]. However, the 
precise mechanisms of how lipid peroxidation actually 
causes the membrane to disintegrate are elusive. Impor-
tantly, the glutathione (GSH) peroxidase 4 (GPX4) rou-
tinely prevents ferroptosis and lipid peroxidation, specif-
ically of a recently identified phosphatidylethanolamine 
residue (see below). 
Ferroptosis has first been described in renal tubules 
that no longer underwent necrotic transformation upon 
addition of a second generation ferrostatins [10]. This led 
to the investigation of third-generation ferrostatins that 
were identified in screening approaches on small mole-
cules. These small molecules are stable in vivo and there-
Box 1. Open questions on regulated cell death in AKI
How does the type of cell death relate to the intensity of AKI?
For a single cell, it is hard to reason that it matters how exatly it dies. However, it does matter for the surrounding tissue and the 
inflammatory response. In the concept of necroinflammation, different cell death pathways are immunogenic to a different extent. 
Whereas apoptosis does not cause and immune response, pathways of regulated necrosis may initiate a detrimental immune cell 
infiltrate that further deteriorates the primary damage [8]. The second wave of death may also be dependent on necrosis and 
 thereby fuel a vicious circle of necroinflammation [13].
Is there a role for apoptosis in AKI? 
Despite the work of decades, it is still unclear if apoptosis has a role in human AKI. Clearly, Bax/BAK-dko mice are protected from 
ischemic [14] AKI and unilateral uretric obstruction [15]. However, the pan-caspase inhibitor zVAD-fmk did not protect mice a 
model of ischemia-reperfusion injury in our hands [16]. In theory, the presense of an immune cell infiltration that contains NK 
cells, T cells and neutrophils might argue towards a necroinflammatory component.
Can autoimmunity be explained by failure to remove necrotic cellular debris?
Failure to remove necrotic debris by a process referred to as LC3-associated phagocytosis (LAP) continuously stimulates the 
immune system, results in the generation of anti-nuclear antibodies (ANAs) and antibodies against double-stranded DNA 
 (ds-DNA antibodies) and drives autoimmunity. [17, 18]. This may not exclusively be the case for systemic lupus erythematosus 
(SLE), but also for other autoimmune diseases. One such example that causes AKI may be ANCA-associated vasculitis [19].
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fore facilitated the assessment of ferroptosis-interference 
in vivo in models of AKI. In our hands, the ferrostatins 
16–86 was the most potent single compound to preserve 
the renal structure and function in a model of severe isch-
emia-reperfusion injury [11]. Strikingly, the mode of ne-
crotic cell death strongly mimics the cellular changes ob-
served in urine sediments upon acute tubular necrosis. In 
handpicked isolated perfused renal tubules, the addition 
of ferroptosis-inducing agents (erastin) resulted in an in-
tercellular chain reaction that we referred to as synchro-
nized RN (SRN) [11]. It is now clear that ferroptosis 
drives this reaction, and in vitro models are being devel-
oped. In parallel, the importance of ferroptosis in AKI 
was confirmed by the genetic depletion of GPX4 in renal 
tubules that resulted in lethal tubular necrosis that was 
sensitive to the application of a ferrostatins [12]. GPX4 is 
a selenocysteine-containing protein (a selenoprotein) 
and the prevention of ferroptosis may explain the need 
for selenium uptake of humans. Clearly, the renal tubular 
system is among the most ferroptosis-sensitive parenchy-
mal structures in the human body. However, as tempting 
as ferroptosis may exhibit a model for nephron loss, from 
an evolutionary perspective, it is not immediately clear 
why humans should conserve an RN-pathway of syn-
chronized necrosis (SRN) as an evolutionary benefit. In 
this respect, ferroptosis may better be interpreted as a fail-
safe rather than an RN pathway. Importantly, life on earth 
requires a system to inactivate highly reactive oxygen and 
reactive oxygen species, especially in cells with high ATP 
turnover. In this sense, failure to appropriately cope with 
the ROS load may result in ferroptosis.
Hardly anything is known about the immunogenicity 
of ferroptosis. As short lived lipid peroxides are highly 
toxic (possibly explaining the phenomenon of SRN), they 
might even kill infiltrating lymphocytes or other immune 
cells. In addition, it is not clear how a wave of SRN might 
be terminated mechanistically. However, ferroptosis was 
only recently described and is certainly under intense in-
vestigation.
Conclusions and Outlook
It remains a major task to unravel the relative contribu-
tion of RN pathway to the overall organ damage during 
AKI. Several complicating factors need to be overcome. 
First, the in vivo models of AKI used today hardly reflect 
the situation of AKI on an ICU or in multimorbid patients. 
Second, our biomarkers of AKI and necroinflammation 
are insufficient. A biomarker panel is needed – not only a 
damage marker or only a functional marker. Third, inhib-
itors of necroptosis are in clinical trials for autoimmune 
conditions, but clear AKI trials remain to be initiated. Fer-
rostatins, to the best of our knowledge, have not passed 
phase 1 clinical trials so far. Finally, the clinically used 
AKIN and/or KDIGO classifications were not correlated 
with long-term outcome of AKI patients and hardly repre-
sent reliable gold standards for clinical comparison.
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